Press Releases | Medtronic

Month Year

Email alerts

Feb 27, 2019

Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation

Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum

DUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian(TM) RF ablation platform, which conducts radio...
Feb 26, 2019

Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)

FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO

DUBLIN - February 26, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute...
Feb 25, 2019

Medtronic Wraps Up Scientific Data Presentations at the Advanced Technologies and Treatments for Diabetes International Conference

DUBLIN - February 25, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a successful conclusion to the 12th International Conference on Advanced...
Feb 20, 2019

Medtronic Announces Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.

DUBLIN - February 20, 2019 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer by its indirectly wholly owned subsidiaries, Medtronic, Inc....
Feb 20, 2019

Medtronic Announces U.S. Commercial Launch of Deep Brain Stimulation for Medically-Refractory Epilepsy

With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication

DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted...
Feb 20, 2019

Medtronic EVP & RTG President Geoff Martha to Speak at Leerink Partners Global Healthcare Conference

DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 8th Annual Leerink Partners Global Healthcare Conference...
Feb 19, 2019

Medtronic Reports Third Quarter Financial Results

Revenue of $7.5 Billion Increased 2.4% Reported; Increased 4.4% Organic

DUBLIN - February 19, 2019 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019. The company reported third quarter...
Feb 19, 2019

Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

GLOBE NEWSWIRE via COMTEX) --DUBLIN - February 19, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from...
Feb 17, 2019

Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

Groundbreaking Microstream(TM) Capnography Study Provides Easy-to-Use Risk Prediction Tool

DUBLIN and SAN DIEGO - February 17, 2019 - Medtronic plc (NYSE:MDT) today announced preliminary results from PRODIGY, a Medtronic-sponsored, prospective, multi-center study to identify people at...
Feb 15, 2019

Medtronic Statement Regarding Revised IN.PACT Post Market Study Data

DUBLIN - February 15, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the...

Show per page